Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BO-112 + Pembrolizumab in Advanced HCC
NCT04777708Phase 1Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2021
- Primary completion
- Mar 2023
- Modality
- Oncolytic Viruses, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nanoplexed poly I:C in hepatocellular carcinoma (HCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Objective Response Rate up to 4 years. Started Oct 2021; status: terminated.
02
Drugs
nanoplexed poly I:C
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04777708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04777708.